arrow
J

Jeremy Ramdial

The University of Texas MD Anderson Cancer Center
H指数:19
被引数:1,473

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

在复发多发性骨髓瘤中,自体移植后使用达鲁单抗±泊马利度胺进行维持治疗:一项2期研究

2026-09-260
OAAI
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

卡非佐米、来那度胺和地塞米松(KRd)与硼替佐米、来那度胺和地塞米松(VRd)在自体造血干细胞移植/移植前诱导治疗新诊断多发性骨髓瘤的比较

2026-08-200
PRE
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

供者特异性HLA错配:单倍型与7/8位点错配无关供者造血干细胞移植联合PTCy

2026-06-170
PRE
D-VRD induction and autologous transplant in patients ≥70 years

D-VRD诱导和自体移植在≥70岁患者中的应用

2026-06-050
OAAI
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

低强度治疗下急性髓系白血病中ASXL1突变的预后影响

Cancer
IF5.1
2026-05-060
OA
Daratumumab-based second line therapy improves outcomes after VRD induction, upfront autologous transplant and lenalidomide maintenance

达鲁单抗为基础的二线疗法在VRD诱导、一线自体移植和来那度胺维持治疗后改善了结局。

2026-05-010
PRE
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

异基因造血干细胞移植对高风险骨髓增生异常综合征患者的影响

2026-03-270
OAAI
Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

在高风险急性髓系白血病和骨髓增生异常性肿瘤中,使用允许性的HLA-DPB1错配和移植后环磷酰胺可降低复发率。

Leukemia
IF13.4
2026-03-090
OAAI
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapies

与疗法相关的非核心结合因子急性髓系白血病的维奈克拉为基础的治疗结局

2026-02-120
OAAI
Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation

来那度胺维持治疗在延迟或挽救性自体造血干细胞移植后的应用

2026-01-010
PRE
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma

延迟或挽救性自体造血干细胞移植治疗多发性骨髓瘤的结果

2025-12-050
PRE
Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant

多发性骨髓瘤患者伴有1p缺失行自体干细胞移植后的结局

2025-08-050
PRE
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE